Book Review: The Essentials of Patent Claim Drafting

January 8, 2012

The Essentials of Patent Claim Drafting by Morgan D. Rosenberg is a straightforward practical guide to drafting claims, aimed at the beginner. To the extent that one can learn to draft claims from a book, this is not a bad tutorial.

As with many such works however, it is strongly biased to mechanical type drafting. Software and physics are covered to some extent, but the focus is heavily on the predictable arts. The claim style is a little long-winded and pedantic for my taste. The focus is on USPTO requirements, but nevertheless, in my opinion, a chapter dedicated to the differences in US approach, from say, that of the EPO, would be a valuable addition.

The thrust is on drafting claims for obtaining patents. System, Method, product-by-process, Jepson, Markush and Beauregard  claim styles are discussed and illustrated, as are means+function, which are discouraged. Free Beer claims are not mentioned unfortunately. Nor are other claim styles disallowed in the US such as omnibus claims.  Since ultimately a patent might be litigated, there should perhaps be some discussion on claim construing in Marksman hearings and the need to make sure that terms cannot be misinterpreted.  Nevertheless, a useful guide for beginners.

  • Paperback: 224 pages
  • Publisher: Oxford University Press, USA (November 17, 2011)
  • Language: English
  • ISBN-10: 0199856354
  • ISBN-13: 978-0199856350
  • $125

Rules for Patent Drafting

January 8, 2012

There are many books that relate to claim drafting. Rules of Patent Drafting by Joseph Root is different in that it relates to drafting patent specifications, not merely the claims. Its premise is that when a patent is litigated, terms not mentioned in the claims but used in the specification may be read into the claims by the court during claim construction in the so-called Marksman Hearings, so it is important to carefully consider the specification as a whole when drafting applications, and not merely the claims. The book implicitly rejects the idea propagated by do-it-yourself patent guides, that the inventor can write his own application and simply have a patent agent or attorney draft the claims.

Instead of moaning about what the courts do to patent claim interpretation in Marksman hearings, the book suggests internalizing the court’s approach and reconsidering one’s patent drafting, and provides rules for so doing. In particular, the book suggests writing longer and more detailed disclosures, while taking care not to describe optional features as necessary ones, of course.

One interesting insight about the claims is that since an independent claim has to be construed as being broader than its dependencies, a purpose served by claiming seemingly trivial elements in dependent claims is not to provide a fall back position, but rather to prevent these elements being construed as essential to the invention.

The contents and insights are refreshingly different from the type of thing that seems to be rehashed in books aimed at beginners. Furthermore, the author, Joseph Root,  supports his contentions and illustrates his approach with reference to Federal Circuit Court of Appeal decisions.

Unlike most books on claim drafting that seem to focus on mechanical or electronic systems, the author relates to both the predictable and the unpredictable arts, and instead of simply saying that they are no longer popular, doesn’t shy from tackling means claiming in a thorough manner.

What is particularly refreshing though, is the style. The author emphasizes his points with similes and metaphors taken from an impressive range of books, films, and TV series. Despite thoroughly addressing weighty subject matter, the book is not a heavy read.

ISBN13: 9780199734924
ISBN: 0199734925
Published: February 2011
Publisher: Oxford University Press USA
Country of Publication: USA
Format: Paperback
Price: £135.00

America Invents at Bar Ilan University

January 5, 2012

Yesterday, I had the privilege to attend a very well run and well constructed full day program dedicated to the America Invents Act. The highlight of the program, was, without a doubt, a lecture by Judge Randall Rader, the Head of the US Federal Circuit Court of Appeals.  Judge Rader is in the enviable position that his interpretation of the amendment to the patent law is likely to prevail when they are litigated. This is reason enough to hear him. Additionally, Rader is an accomplished speaker and his presentation was highly entertaining.

Rader started by wishing everyone a Good Year (Shana Tova) in heavily accented Hebrew, but then noted that it wasn’t actually the Jewish New Year at all. He went on to say all sorts of nice things to the appreciative audience, about Israel being heavyweight patent filer despite its small population, and that Israelis have a survivalist mentality that serves them well in the modern era of fierce global competition.

The main thrust of Rader’s presentation focused on what he saw as being the central issue of the America Invents Act; that America becomes a first-to-file regime, abandoning their anomalous first-to-invent system, thereby coming into line with the rest of the world. However, Rader noted with satisfaction, that the grace-period has been retained. In his opinion, this protects inventors from killing their patenting chances by first publishing or demonstrating their innovations. Rader expressed his hope that now that the US had made a massive move towards Europe in adopting the first to file regime, that perhaps Europe should reciprocate by also adopting a grace period.

Rader invited questions from the audience, and it seemed that many of those present were less than convinced that the judge was correct that the amended law reduced uncertainty and really promoted greater similarity between countries. I pointed out that as far as both novelty and inventive step (obviousness) are concerned, there was still significant differences. My good friend Larry Rublin made a short and succinct observation that made it apparent that he was proficient at defining systems, as would be expected from a patent attorney. In contrast to most of the audience, Larry’s mentor, Heidi Brun, went on record to the effect that she believed that the grace-period was positive, since it gave something to tell the inventor who had already exhibited.

I found myself realizing that my preference for first-to-file was that it provided certainty based on simple to establish facts.  Judge Rader apparently believes that patent protection is a reward for inventing and contributing to knowledge, and so the uncertainty that prior publication brings should be allowed, despite it somewhat complicating the system. I suspect that Heidi’s position reflected both her personal empathy with the inventors and also the patent attorney’s (self) interest to enable clients to protect their IP. Another reflection that came to me whilst listening to Judge Rader, was how unfortunate it is that Israel does not have dedicated IP judges. The final thought, seeing Rader’s stars and stripes necktie, and the green with white polka dot thing wore by sponsoring attorney Colb, was that there is apparently a correlation between the eminence of the speaker, and the ridiculousness of the tie.

The pastries served during the coffee break were freshly baked and delicious, and there was a selection of both tea and herbal infusions. Disappointingly, the coffee was either instant or botz (hot water poured over ground coffee).  Nevertheless, the speakers were sufficiently interesting that quality caffeine wasn’t necessary to stay awake.

Judge Rader was followed by a light-hearted but thought provoking presentation by Dr Dan Goldstein and Benjamin Fishman, both senior patent attorneys at Colb, each wearing formal business suits and fairly conservative ties. They proposed a number of reasonable scenarios and amply demonstrated that the law, as legislated, left a lot of uncertainly, and presumably the courts will have their work cut out over the next few years. Judge Rader was teased a little in the presentation, but he took it well, and showed his sharp legal mind  in one of his responses, by succinctly distinguishing between the aspects of the scenario presented that were a consequence of the new legislation, and the aspects that were equally problematic under the old law, or simply due to the complications of plausible, if convoluted, scenarios.

After lunch, comprising filled rolls and an orange vegetable soup, the program continued with sessions compered by Dr Yoav Mazeh and Dr Ofer Tur-Sinai, young lecturers at ONO Academic College, showing a nice collaboration between the two closely situated law faculties.

Colb himself spoke about the statistics of reexamination and came to the conclusion that after investing large sums of money, most clients obtain a patent that if they tried to enforce, would be invalidated or at least considerably narrowed, and suggested that attorneys should tell their clients.

Dr Ofer Tur-Sinai chaired the final session. David Zviel, Patent Counsel of NDS, spoke about the ethical conflicts faced by in-house counsel. David argued that the pressure resulting from dealing with ethical dilemmas faced by pin-house counsel were greater than those faced by attorneys working for patent firms. Unfortunately, for obvious reasons, he didn’t illustrate this assertion with concrete examples.

Professor Orli Lobel cut an impressively elegant figure in a well tailored jacket, and stylish designer jeans. For some reason she postulated that it was easier for a large corporation to make a decision and to pursue a policy than it was for an independent inventor. She backed up her position with some empirical evidence culled from the effect of the reform to the Canadian patent law that was in some ways similar to the American Invents Act. Her presentation was followed by one by Suzanne Erez, in-house IP counsel for IBM Israel, who wore a more homely knitted dress and flat shoes, and who walked around a lot whilst presenting. It was not clear whether she was gently poking fun at the earlier and mre formal speakers, or if Suzanne simply and justifiably felt at home with the audience of her peers, and felt no need to dress to impress. She focused on key issues that the act could and should have related to. All the presenters significantly contributed to the program and even without Judge Rader’s keynote presentation, the day would have been informative and worthwhile.

The event attracted about 100 people, and for Judge Rader’s presentation, the lecture hall was packed,  with people standing in the aisles.

This was the fourth such annual event hosted by Bar Ilan University and co-sponsored by the Jerusalem College of Technology and S. T. Colb Patent Attorneys. Although the food served at last year’s conference, held at the Tel Aviv Hilton was of a higher quality,  in my opinion that program, featuring attorneys from Fish Richardson was a little too commercially oriented for academic institutions like Bar Ilan and JCT to be identified with, despite being of a high standard.

It was certainly a better program than that offered the year before where the Bar Ilan – Colb collaboration examined the future of business method patents  after Bilski, despite pre-empting the decision it was supposed to analyze. It also featured too many academics having little knowledge of real patent issues.

In summary, this year’s program was informative, topical, well organized, well attended and thoroughly enjoyable. I congratulate all the speakers, and thank Professor Bitton, Seth Heller and Sanford Colb for organizing the event. We note with pleasure that Professor Arieh Reich, the Dean of the Bar Ilan Law Faculty announced that this January IP event would continue to be held annually.


America Invents, and you can learn about it in Israel!

December 18, 2011

Bar Ilan university are hosting a full day conference on 4 January 2012 to debate the ramifications of the changes in the US Patent Law wrought by the America Invents Act.

To register, or to receive more details, please contact Dr Miriam Bitton:   miriam.bitton@mail.biu.ac.il

The event is sponsored by S.T. Colb and will be held in the Wohl Center, Hall 1 of the Bar Ilan Campus.

The program hasn’t been released yet, but apparently Judge Randall Rader the Chief Judge of the United States Court of Appeals for the Federal Circuit will be lecturing, so regardless of who else is presenting, the event will be worth attending.

COMMENTS

Two years ago, the dynamic Bitton-Colb duo gave us a conference titled, After Re Bilski Now What? which unfortunately took place several months before the Bilski decision was heard by the Supreme Court.  See  here. That conference, spread over two days, was characterized by a lot of vacuous waffle and prophecies that never materialized. We therefore applaud the decision to concentrate on recent historical (and perhaps historic) amendments to the US Law.

In January last year, S.T. Colb teamed up with Fish Richardson and held an event on patent litigation in the US. That event was again cosponsored, at least officially, by Bar Ilan.  For more details, see here.

We suspect that the refreshments at Bar Ilan will be less of a high standard, but lower than the fayre at the Hilton. Looking forwards.


JMB, Factor & Co Hosts Seminar on Medical Device and Life Sciences Patent Protection, Reimbursement and FDA Approval

November 8, 2011


This afternoon, JMB, Factor & Co. held a seminar on patenting medical device patents. I spoke about using FDA approval as a back door method of enforcing therapeutic patents in the US. My colleague Dr Moshe Tritel spoke about obtaining effective patent protection for gene sequences and pharmaceutical molecules and Dr Irv Treitel gave a wide-ranging presentation on various aspects of protecting medical devices, including the changes resulting from the new America Invents legislation, whether or not to conduct searches and the advantages of design patent protection, continuations and continuations in part.

Each of the patent related talks was kept to 10 minutes, so the three talks were focussed and fast-moving and took a mere 30 minutes in total.

Alan G. Minsk, a partner of Arnall Golden Gregory LLP in Atlanta, spoke about obtaining FDA approval and gave a very polished presentation that was peppered with anecdotes.

After a short break, Mr Amir Inbar of Mediclever spoke about Reimbursement, and then a couple of our clients, Mr Omer Carmel of Niti Surgical Solutions and Mr Avraham Harris of Sythezza Molecular Detection Israel, spoke about their practical experiences with the issue raised. The conference room was packed, and it seemed that the audience found the event informative. In contrast to what so often happens at IP events in Israel, my partner, Jeremy Ben David, who compered the seminar, managed to keep the event on schedule, and although the break was 5 minutes late, the event, with seven speakers, finished bang on time.

We acknowledge the help of the American-Israel Chamber of Commerce who co-sponsored the event.

 


Viagra patent holds up

August 17, 2011

Teva’s challenge to the validity of Pfizer’s patent for Viagra was dismissed by U.S. District Judge Rebecca Beach Smith of Norfolk, Virginia, in a 110 page opinion.

 

“Teva has not shown by clear and convincing evidence that the patent is invalid,” wrote Smith who went on to state that “There is utterly no evidence” to support Teva’s claim that Pfizer intentionally withheld documents from the U.S. Patent and Trademark Office. For more information see http://www.bloomberg.com/news/2011-08-15/pfizer-wins-viagra-patent-infringement-case-against-teva-pharmaceuticals.html

 

 

 

 

 


Israel and US Patent Offices Announce a Superhighway – But so what???

June 25, 2011

I read in the weekend edition of Israel’s Mekor Rishon newspaper that the USPTO and the IPO have announced a super-highway, designed to streamline patent examination. The author of the article,  Ori Israel Paz, informs us that the wait between filing and issuance of Israel patents is notoriously long and that this initiative will make a difference.

Not for the first time, the journalist responsible, has taken a press release from the patent office at face value. Sorry to sound like an epicurean, Doubting Thomas, agnostic, or plain cynic, but I don’t believe a word of it.

Here’s why:

In Israel, Section 18 of the Patent Law requires applicants to submit citations and search reports from other patent offices in a timely manner from when a Notice of Imminent Examination issues, until allowance. The USPTO examination is open to the public over the Internet from 18 months from priority. The Examiners can and do check up what is happening in the US.

Under section 17c of the Israel patent law, once a US patent issues, an applicant in Israel can request allowance on the basis of the US patent, unless there some bar, such as the US patent claiming method of therapeutic treatment or relating to something that was documented in a publication within the grace period of a year prior to first filing that exists in the US but not in Israel.

In order to comply with WIPO requirements as an International search Authority, the Israel Patent Office has been recruiting examiners at an accelerated pace to have 100 examiners on their records.  There are about 7000 applications filed in Israel annually and more than half are allowed under Section 17c, without substantive examination. This means that there are more than enough resources for the Israel Patent Office to examine applications in a timely fashion and on the whole it does.  Backlogs have dropped in all technologies.

In contrast, the USPTO is in a mess with an enormous backlog, but the entire Israel Patent Office staff won’t make much of a difference. Under current Israel Law I don’t see how the Israel patent office can share submissions made by applicants before the end of the examination process when the granted patent is made available for opposition purposes, as the application and file wrapper are not available for inspection until then. Additionally, since the examination documentation that is sent back and forth between the examiner and the applicant’s representative are in Hebrew, one wonders how useful access to the Israel patent prosecution file will be to most US Examiners.


Fish Richardson Holds Litigation Seminar in Israel

January 2, 2011

Fish Richardson and S. T. Colb, prominent US and Israeli patent attorney firms respectively, joined forces to hold an event on US Patent Litigation Developments today. It being 2 January 2011, this was certainly the best Israel IP event so far. It will also be a tough act to follow.

The event was held at the Tel Aviv Hilton and was by invitation only. In addition to clients of the two firms, many Israeli IP practitioners were invited, and there was a fair sprinkling from the various IP Firms.

Surprisingly, the event was also sponsored by Bar Ilan University Law Department and by the Jerusalem College of Technology (JCT - Machon Lev); surprising that there was university sponsorship, since the event was clearly commercial rather than academic in nature. There were a couple of rows of Bar Ilan law students, but the event was well attended by practitioners, and there wasn’t really a need for bums on seats.

This time last year, Colb and Fish Richardson joined forces to sponsor a more academic  program at Bar Ilan University that was spread over a couple of days and featured a bunch of college professors waffling about the ramifications of the Bilski decision. See Bar Ilan University Holds Premature “After Re Bilski” Conference. That event was a little surreal since it occurred some six months before the Supreme Court ruling in the Bilski case!!!

In contrast, today’s event was interesting, of more practical relevance and far better organized.

An extended breakfast of miniature croissants, rolls and jam, burekas, etc. and fresh coffee was served in 10 minute breaks after each session through the morning.

There were the usual words of welcome. However, due to traffic, I was unable to attend the first session. A 9:00 am start on a Sunday morning at the Tel Aviv beach front is a little difficult for out-of-towners like myself.

The second session includes a review of recent litigation and trends, which was quite comprehensive. As I follow US developments, I did not learn much. Nevertheless, the presentation was informative and I assume that those less actively following trends did find it very worthwhile.

There was an interesting session before lunch on what should one do in particular scenarios. From the show of hands, it was clear that the position suggested by the session leaders was not that which every practitioner in the room would have taken.

The issue of inventor fraud was neatly raised and dealt with by Dan Goldstein, a senior attorney at Colb. In the charges brought by the Israel government in the Omrix case, The largest IP case brought in Israel to date, Colb was criticized for a legal opinion provided to the firm, that Professor Martinowitz was not the inventor – see state-of-israel-sues-omrix-for-nis-500-million By raising the issue themselves in this manner, embarrassing questions from the audience were effectively avoided. The session also covered the issue of what should be made of record in the US file wrapper. In general, I felt that the session leaders were correct regarding what should be made of record. Certainly, the presentation gave food for thought. 

It wasn’t just food for thought though. A buffet lunch followed, which was really excellent. the only disappointment was that the chopped liver served by the hotel seemed to be left over from the Sabbath and is apparently not up to the standards Colb has set at his infamous INTA receptions.

Taking my reporting seriously, I sampled the various cakes and mousse in the name of IP research, and can assure readers that the poppy-seed pie was truly excellent, and everyone got their just desserts.

The afternoon session kicked off with a mock Marksman Hearing. Adding unnecessary but enjoyable calories, there was also chocolate buffet mid-afternoon. 

The program was wound up with a simulation of a cross-examination of an expert witness presenting his report of costs.  After the event, we were invited back to dinner at Colb Farm, but as I decided that I had eaten more than enough, I left whilst I could still get into the car.

The Fish Richardson giveaway was a PU styrofoam fish. Aharon Factor, our Head of Trademarks and my brother, has recently been blessed with a baby girl, so I shall convert the souvenir into a pram decoration for the future IP professional to bash about.  

Fish Richardson is the third US litigation firm that has come to Israel looking to drum up work. Last year saw Quinn Emanuel holding a first event, that was a half day program about them mostly. They then came back to hold a mock trial, but since that was cleverly scheduled to clash with INTA for some reason, I was unable to attend. Finnegan held a structured and in-depth program together with the IPR. See US Litigators Come to Israel Looking for Clients for more details. The partners representing the three firms were professional, suave and savvy, and very pleasant. It is difficult to choose between them as each has surveys and statistics that clearly show that they are the number one US litigator firm. It seems to me that this is a zero sum game, with the number of Israeli firms that are able to sue for patent infringement in the US remaining limited and fairly constant. 

Difficult to tell which firm I’ll recommend to clients with IP litigation issues in the United States. Meanwhile, I find these events both informative and entertaining.  They offer a welcome opportunity to keep in touch with local colleagues as well. I congratulate all involved in hosting the event, and thank them for inviting me.


Time Warner Cashes in on Quidditch

December 2, 2010
Quidditch through the ages

 Times Warner has tried to appropriate a trademark for Quidditch. See Studio trademarks ‘Quidditch’ lingerie and other similar stories on the web. 

Quidditch fans will be grateful to Times Warner for including footage of the World Cup in a recent Harry Potter film. The sequences of Hogwarts inter-house competition matches, though staged and definitely ‘little league’, nevertheless promote the sport, particularly amongst Muggles.

That said, wizards have been playing Quidditch for centuries as documented in Quidditch Through the Ages by Kennilworthy Whisp which discusses the game from the 14th Century onwards.

Thus Times Warner claiming a trademark on the term is akin to the producers of Field of Dreams claiming rights to baseball or that of Rudy, the Longest Yard, Remember the Titans or Invincible claiming rights to American Football. Shame on them.

 


PCT Forum Shopping – a Trap for the Unwary

October 9, 2010

An Israeli entity with all Israeli inventors lost priority rights in the US for a PCT application based on a US Provisional Application. This unfortunate incident highlights a trap for the unwary. This decision may be a tempest in a teapot with little practical importance.

 

 

Background

My regular readership may remember that, in the past, I have advocated taking advantage of different national holidays and weekends around the world to informally extend the 12 month Paris Convention deadline for filing PCT applications by a day or two.  See  Israel Patent Office Closed for Rosh Hashana, Yom Kippur, Sukkot and Id Ul Fitr

The incident

Apparently, a provisional application was filed in the US on 11 October 2005, and then, just over a year later, on 15 October 2006, a PCT application was filed in Israel. Since the Israel Patent Office was closed over the period 7th – 14th October 2006 due to the festival of Sukkot, the PCT was filed on Sunday 15th October 2006 when the patent office reopened and was considered as timely filed by the PCT authorities who recognized priority from the provisional application.

Eventually, a US national phase entry was filed claiming priority from the provisional application. However, the US Patent Office pointed out that since the priority application was a US (provisional) application, under Sections 119(e) and 363 of the US Patent Law and Section 8 of the PCT Agreement, the issue was whether the USPTO in Arlington Virginia was open or not, or more formally, if there was a holiday in Washington DC.

The USPTO’s decision points out that the application could have been filed on the 11th October 2006 in the US, despite it not being a competent receiving office. More relevant perhaps, it could have been filed at the International Bureau in Geneva that day.

Consequently, the USPTO has ruled that as far as the US is concerned, the priority date has been blown, and the effective filing date of the US application was 15 October 2006 and not 11 October 2005.

The decision is subject to appeal.

Comments

The USPTO seems to be over-ruling the PCT Convention Rules which seem fairly explicit. See http://www.wipo.int/pct/en/texts/rules/r2.htm#_2_4 and http://www.wipo.int/pct/en/texts/rules/r80.htm#_80_5

 Thankfully it wasn’t one of our cases. It could have happened to anyone. Only a week and a half ago we had a Paris Convention deadline over Sukkot for an application first filed as a provisional for one of the Israel Universities, who  also dictated that we file the priority application as a provisional. Luckily, the lawyer who handles our PCT filings double-checked with the patent office, so we filed early.

Where the client can afford it, we recommend filing in the US concurrently with filing a  PCT application as the US is frequently the most important jurisdiction and an early allowance is valuable. By selecting the European Patent Office as the International Search Authority the applicant can decide on where to file with searches from both the EPO and the USPTO, which provides a higher degree of certainly that the relevant prior art has been flushed out.

The Specific Case – storm in a tea cup

As the Israel Commissioner of Patents saw fit to white-out the name of the applicants, the various application numbers, etc. I shan’t publish this information. Others as nosy as me, will have little trouble making a shortlist from the filing date!

That exercise was quite revealing actually. I myself filed an application for Amitech (a chip substrate manufacturer) back on 15th October 2006 for something claiming priority from an 11th October 2005 filing.  In that instance, the priority application was an Israel Application. It is not totally clear how relevant that is. The decision certainly mentions that the priority document was a US provisional, but it is not clear whether this was the reason for the USPTO over-riding the PCT Convention rules.

Furthermore, three PCT applications were filed on that day by different Israel universities, each claiming priority from applications filed on 11 October 2005 - two of them claimed priority from US provisional applications - one was for the same university that I filed an application for a week ago and could easily have filed after Sukkot were it not for a super-efficient back office.

Interestingly, the three university applications filed that day were handled by different firms. There were also two applications filed by Israel industry that claimed priority from provisional applications. This indicates that at least eight fellow practitioners made the same ‘mistake’.

As a PCT application was filed, one presumes that the specific application was not disclosed prior to filing the provisional and could have been filed in other jurisdictions. If this is the case, the damage is minimal since the US operates a first-to-invent and not a first-to-file regime. Even without formally recognizing priority from it, the US provisional is compelling evidence that the inventors had conceived of their invention and reduced it to practice by the provisional filing date. The filing of the Provisional and the chain of events establishes diligence in pursuing a patent in the US as well. Thus it seems likely that no real harm has been done by this decision and the case is a storm in a teacup. 

Where things could be nasty though, is if the original provisional filing was made on 11th October 2005 for something to be published between 11th October 2005 and 15th October 2005.  That sort of thing can and does happen with inventions coming out of universities where the applicant needs a filing date prior to publishing a scientific paper or conference proceedings. Indeed, of the 6 or 7 applications filed in Israel on 15th October 2006 that claimed priority from an application filed on 11 October 2005, three were filed on behalf of university tech transfer companies. In such a scenario the refusal by the USPTO to accept priority from the provisional will invalidate the US patent. This could be very painful for those concerned.

Another way to look at this is that in essence, the USPTO has so far decided that since the PCT application designating the US was, under US statutory law, a US non-provisional filing, it had to have been filed with an effective date under US law within the statutory one-year life of the US provisional application (if any priority benefits were to be accorded).  The only exception would be if based on US weekends / holidays when a later filing will, under proper circumstances, still suffice under US law. 

To attempt to overcome the decision, the US Attorney of Record tried arguing that the USPTO often creates additional US holidays by executive fiat, such as when record snow fall or some other emergency effectively shuts down Washington DC.  Consequently, the absence of specific statutory authority relief in this instance was not really an obstacle and since the USPTO has taken a position that conflicts with PCT Rule 80.5 as well as with Articles 27 and 47, this seems a reasonable approach. The argument has so far fallen on deaf ears at the USPTO.

Nevertheless, the USPTO does not consider its latest action as constituting a “final” administrative action and therefore a court action under the Administrative Procedures Act would be premature.  In any event, since the current record does not indicate any factual need for the claimed priority benefit, the whole issue of priority in this specific case may be moot, and perhaps could be reconsidered if and when the claimed priority benefit becomes materially relevant.  Should the priority claim for the specific case ever become an real issue, the USPTO’s decision can be challenged at any point prior to 6 years from the “final” agency action.


Follow

Get every new post delivered to your Inbox.

Join 93 other followers